

# NKBCI NEWSLETTER

JULY - SEPTEMBER 2022



## AWARDS AND RECOGNITIONS

---

Dr. Ziad Salem, a legacy that inspires others to dream more, do more, and become more	2
Emirates Oncology Society Awards Dr. Naji El-Saghir	5
Congrats to our Doctors	6

## AWARENESS CAMPAIGNS

---

Sarcoma Awareness Month	9
Myeloproliferative Neoplasms Awareness Day	10
FOR HER Patient Support Workshop Emphasized Hope and Reality of Life with Breast Cancer	11

## FUNDRAISING EVENTS

---

Cancer Support Fund at AUBMC Welcomes People to People Aid and U.S. Ambassador Dorothy Shea	14
---	----

## SCIENTIFIC EVENTS

---

NKBCI receives a Medical Education Grant from Pfizer and Merck	18
Initiation of Molecular Tumor Board	19
BEYOND, a randomized double-blind placebo-controlled clinical trial of the newest disease modifying drug for beta-thalassemia, Luspatercept	20

## IN THE SPOTLIGHT

---

## PUBLICATIONS

---



FAREWELL  
DR. ZIAD SALEM

## Dr. Ziad Salem, a legacy that inspires others to dream more, do more, and become more

On August 11, 2022, the Naef K. Basil Cancer Institute (NKBCI) at the American University of Beirut Medical Center (AUBMC) honored Dr. Ziad Salem for more than 40 years of utmost dedication in serving AUB and its medical center and for his great contributions to the Hematology Oncology Division. Ever since the directorship of Dr. Taher at NKBCI, Dr. Ziad Salem had gracefully donated all his clinical income to serve NKBCI, its staff, and its operations, while he remained practicing with the same clinical excellence, work ethics, work hours and dedication he has always maintained, beyond the call of duty.

The ceremony was attended by AUB President Fadlo R. Khuri, Raja N. Khuri Dean of the Faculty of Medicine and Vice President for Medical Affairs Raymond Sawaya, Executive Associate Dean for Faculty Affairs and Chairperson of the Department of Internal Medicine Fuad Ziyadeh, Associate Vice President for Advancement and Communications and Director of NKBCI Ali Taher, Head of Hematology Oncology and Director of Breast Center of Excellence Nagi El Saghir, the Salem family, a number of dignitaries, and members of the AUB and AUBMC community.

Dr. Fadlo Khuri, President of AUB



"Numerous family members were treated by Dr. Salem and our trust in you is unlimited, I want to thank you for all what you did [...]"

Dr. Ali Taher, Director of NKBCI



"What is even more telling of his integrity, is that over the past few years, despite the institution and the country going through the most challenging times, Ziad, who likely has had endless opportunities elsewhere, stayed loyal to his home institution."







Dr. Naji Saghir

“

Dr. Ziad Salem is a great, smart, and very knowledgeable clinician and teacher. Ziad is a man of science. He keeps himself on top of all aspects of hematology oncology. He never misses any of our educational activities, lectures, tumor boards, and grand rounds. His patients were indeed very lucky to have him as their up-to-date treating oncologist.”





## Dr. Ziad Salem

### Short Biography

Dr. Salem has led the Hematology Oncology Division and evolved it into a world-class division that became reference for Lebanon and the region. He attained his MD from AUB in 1973 and earned his residency degree in 1975. He earned the prestigious Alpha Omega Alpha Honor Medical Society in 1972. He joined AUB as an assistant professor of internal medicine and laboratory medicine in 1980 and served as head of the Hematology Oncology Division from 1986 till 2001 and head of the tumor registry at AUBMC from 1987 till 1990. In 1993, he was promoted to associate professor of clinical medicine. He won the Salim El-Hoss Humanism and Professionalism Award in 2014, as well as the Special Merit Award of the Department of Internal Medicine in 2019.





## Emirates Oncology Society Awards Dr. Naji El-Saghir

In its 3rd Annual Conference September 2- 3 2022, the Emirates Oncology Society (EOS) awarded Dr. Naji El-Saghir the "EOS Lifetime Achievement MENA Oncology Award" for his dedication and contribution to the oncology field. This conference collaborated with eminent faculty from MD Anderson Cancer Center, to bring latest advances in the management of various cancers, as well as the most efficient models for implementing these updates into clinical practice. The conference heavily relied on digital platforms in presentations, discussions and analysis which allowed for a successful digital experience for all participants.





## Congrats to our Doctors



**Jean El Cheikh**

American University of Beirut Medical Center

Beirut , Lebanon

Associate Editor  
Cell and Stem Cell Transplantation

### **Dr. Jean El-Chiekh**

was promoted to Associated Editor in the journal of Cell and Stem Cells Transplantation in Frontiers, added to his already existing role as Associate Editor in the journal of Hematologic Malignancies also in Frontiers for the past years.



### **Dr. Mohammad Hasan Hodroj**

was elected to the membership of AUB Chapter of the Alpha Omega Alpha Honor Medical Society. This decision was based on his excellent academic and professional performance and on his potential for a distinguished career in the medical profession.



WHILE DR. SALEM SPENT 40 YEARS  
GIVING AT AUBMC, DR. SAWAYA  
CAME BACK AFTER 40 YEARS TO  
SERVE THIS BELOVED INSTITUTION





# AWARENESS CAMPAIGNS



## Sarcoma Awareness Month

During the Sarcoma Awareness month of July, the NKBCI posted a series of awareness pitches on its social media platforms. A sarcoma is a rare type of cancerous tumor that develops in bone and connective tissue, such as fat, muscle, blood vessels, nerves, and the tissue that surrounds bones and joints.





## Myeloproliferative Neoplasms Awareness Day

Myeloproliferative Neoplasms (MPNs) are a group of rare cancers in which too many abnormal red blood cells, white blood cells or platelets develop in the bone marrow. MPNs are more commonly diagnosed in older people, and to a lesser extent in younger ones


On the occasion of the MPN awareness day (September 9), Dr. Iman Abou Dalle Assistant Professor in Malignant Hematology at NKBCI, held a patient educational workshop to improve their knowledge on diagnosis, prognosis, and symptoms management. This workshop acted as a venue that successfully solicited patient interaction. As such, patients were bold in sharing about their varied experiences in the symptoms they face in their day-to-day life like itching, insomnia, and bone pain. As a result of the workshop, participants agreed to create a hub for patient support and to meet yearly to exchange their struggles, updates and successes.



في أمراض التكاثر النقوي، يمكن أن يؤدي الإنتاج الزائد لخلايا الدم إلى مشاكل في تدفق الدم وإلى مضاعفات مختلفة مثل:



النزيف



تخثر الدم



تطور المرض إلى سرطان الدم



قدرة نخاع لم على خلايا دم كافية



7453 likes

Sarcoma

Sarcoma

View all 100 comments



AUBMC  
Beirut, Lebanon

There are three main types of MPNs



**Polycythemia vera (PV):**  
too many red blood cells build up



**Essential thrombocythemia (ET):**  
too many platelets build up



**Myelofibrosis (MF):**  
too many blood cells and fibers build up



**Chronic Myelogenous Leukemia (CML):**  
too many white blood cells build up



7453 likes

Sarcoma

Sarcoma

View all 100 comments

#Sarcoma

## FOR HER Patient Support Workshop Emphasized Hope and Reality of Life with Breast Cancer

In addition to therapeutic innovations and concerns about availability and access to proper disease management and medication for all patients, the oncology community—especially the breast medical oncology community—has become more attentive lately to quality-of-life issues that patients with cancer face.

In that line, the Lebanese Breast Cancer Foundation (LBCF) has been organizing support group meetings and workshops for patients with advanced breast cancer regularly for the last 10 years. Lately, LBCF resumed its in-person activities and organized a workshop for patients and caregivers called FOR HER, supported by SciencePRO and sponsored by Pfizer. The workshop included formal lectures, question-and-answer sessions, and an open forum for discussion between a faculty composed of two oncologists, Dr. Naji ElSaghir and Dr. Fadi Nasr, from Saint Joseph University in Beirut, psychologist Hiba Salem from AUBMC, sex therapist Sandrine Atallah, life coach Grace Khleif, oncology nurse Latifa Shihab, nurse and breast oncology specialist Rebecca El-Asmar, and breast cancer survivor and new president of LBCF Mirna Sabbah Hoballah, with an audience of breast cancer survivors, advocates, patients, and caregivers.

It was amazing to see how eager patients were to hear about recent advances in therapy as well as dealing with effects of cancer diagnosis and metastasis on their lives. They expressed gratitude knowing that a multidisciplinary team is involved in making plans of treatment for them and for following up on their care. Emotional and sexual issues for patients with advanced breast cancer and their partners were openly discussed. Acceptance, coping, and adjusting to breast anatomical changes, body image, and premature menopause were debated. It was obvious that relationships with family members and children, management of family conflicts, daily schedules, and social activities matter a lot and should be openly discussed and supported.

This workshop that included medical teams as well as patients, caregivers, survivors, and advocates was a great learning experiences for all parties.







## FOR HER PATIENT SUPPORT WORKSHOP



# FUNDRAISING EVENTS






## Cancer Support Fund at AUBMC Welcomes People to People Aid and U.S. Ambassador Dorothy Shea

Beirut: The Cancer Support Fund at the American University of Beirut Medical Center was pleased to welcome People to People Aid founder Wasseem Kabbara and U.S. Ambassador Dorothy Shea as part of People to People Aid's donation of much-needed support for cancer patients. This donation, valued at more than \$1.4 million, is part of a \$5 million dollar global donation of chronic, psychotropic and cancer medications that arrived in Lebanon last week, and comes courtesy of People to People Aid in partnership with Direct Relief and MAP International.

On August 17, 2022, Ambassador Shea and Mr. Kabbara visited the Cancer Support Fund at AUBMC and were received by Ms. Hala Dahdah Abou Jaber, President and Founder of Cancer Support Fund, Mr. Joseph Otayek, AUBMC Medical Center Director, Dr. Imad Baalbaki, Senior Vice President for Advancement and Business Development, Dr. Kamal Badr Executive Associate Dean for Medical Education, Dr. Roni Zeeny, Director of Pharmacy and Ms Celine Abou Karam, Administrator Naef K Basile Cancer Institute and Cancer Support Fund and many of AUBMC renowned Hematologist Oncologist at the Center.


In her remarks, Ambassador Shea highlighted the help the Cancer Support Fund at AUBMC is providing adult cancer patients to sustain their treatment and to complete their recovery journey. The Cancer Support Fund also aims to support patients psychologically as part of its holistic approach towards recovery.



Ambassador Shea thanked People to People Aid, its founder Wasseem Kabbara, and its American nonprofit organization partners Direct Relief, MAP International, for their cooperation and coordination to contribute much-needed medications which support AUBMC and Lebanon in general.

AUBMC Medical Center Director Mr. Joseph Otayek mentioned the importance of the sustainability of healthcare services and thanked everyone for all the efforts done to support AUBMC's mission in Lebanon and to sustain healthcare services. He noted that "AUBMC has been supported since the start by generous donations from People to People Aid, Direct Relief, MAP international, and others that were essential to our operations and to our patients."

Ambassador Shea toured the Naef K. Basile Cancer Center and visited adult cancer patients who shared their challenging experience and their psychological suffering all due to medications shortage, expensive cost of treatment, lack of national coverage and of social security in addition to many other issues related to patient accessing appropriate and receiving adequate care.



Ms. Hala Dahdah Abou Jaber, Cancer Support Fund President and Founder

“Our goal is to not let down any patient but rather keep hope shining by providing them with the chance to access proper care and treatment,”



HELP US SPREAD THE  
**DONATE**  
CHEQUE | CREDIT CARD | CASH | WIRE TRANSFER



U.S. AMBASSADOR  
DOROTHY SHEA



# SCIENTIFIC EVENTS





## NKBCI receives a Medical Education Grant from Pfizer and Merck

Pfizer EMD and Serono Merck have awarded NKBCI a Medical Education Grant in order to conduct Educational workshop series to increase healthcare professional knowledge of evidence-based treatment options for locally-advanced and metastatic urothelial carcinoma. Thus, strengthen capacity for prospective clinical data collection and future collaborative research. The first in the series of webinars to be held is planned for October.

Bladder cancer is the second most reported cancer among males in Lebanon and highly prevalent in the Middle East region in general. However, due to limited data from national cancer registries, stage at bladder cancer diagnosis and treatment outcomes are rarely reported. Moreover, healthcare practitioners in the Middle East region generally follow international guidelines, but no context-specific guidelines are readily available. As such, the NKBCI with its close ties with the King Hussein Cancer Center in Jordan and existing collaboration with the Oncodistinct Clinical Trials Network aim to improve local and regional capacity for collaborative clinical data collection and research involvement particularly in bladder cancer. The Medical Education Grant will assist it in moving closer to this goal.

THE NAEF K. BASIL CANCER CENTER AT THE AMERICAN UNIVERSITY OF BEIRUT MEDICAL CENTER,  
THE ONCO-DISTINCT CLINICAL TRIAL NETWORK, AND THE GENITOURINARY CANCER WORKING GROUP  
ANNOUNCE THE

### IMMUNOTHERAPY IN UROTHELIAL CARCINOMA SERIES

-MUSCLE-INVASIVE BLADDER CANCER-

STARTING 13TH OCTOBER 2022

17:00 - 19:30, BEIRUT LOCAL TIME, GMT +3

### REGISTRATION

REGISTRATION TO THIS SYMPOSIUM IS FREE! PRE-REGISTRATION IS REQUIRED;  
ONLY THOSE WHO ARE PRE-REGISTERED WILL BE ACCEPTED.

DEADLINE TO REGISTER IS OCTOBER 11TH 12:00PM BEIRUT LOCAL TIME

### TARGET AUDIENCE

THIS SERIES IS DESIGNED FOR UROLOGISTS AND ONCOLOGISTS IN PRACTICE OR IN TRAINING  
FROM THE MIDDLE EAST AND NORTH AFRICA REGION PLUS GULF CORPORATION COUNTRIES

HEALTHCARE PROFESSIONAL DEVELOPMENT CENTER (HPDC)

AMERICAN UNIVERSITY OF BEIRUT, BEIRUT - LEBANON

TEL: +961 1 350000 EXT. 4752 - 4717 | EMAIL: HPDC@AUB.EDU.LB | WEB: HPDC.AUB.EDU.LB



## Initiation of Molecular Tumor Board

The NKBCI and the Pathology and Laboratory Medicine Department at AUBMC capitalized on their strong relationship by initiating the First Molecular Multidisciplinary Tumor (MTB) Board in Lebanon with support from Roche and Accenture. The first MTB was held on September 21.

This Tumor Board is an educational service available for reviewing the Next Generation Sequencing Reports provided to the medical centers by providing insights from Foundation Medicine Inc. (FMI) experts on the genomic findings and their clinical implications. The MTB will be attended by two Foundation Medicine International experts: a Physician and a Genomicist and will be co-chaired by Dr Hazem Assi and Dr Rami Mahfouz.

The screenshot shows a Zoom meeting interface. At the top, there's a meeting bar with participants: Layal Al Mahmassani, Alan Tan, Hiba, International FMI-MTB, Jeannot Kokedjian, and Mohamad Mourad. The main window displays a presentation slide titled "ORD-\*\*\*463-01, Breast invasive ductal carcinoma (IDC)" and "MAPK and mTOR Oncogenic Signaling Pathways". The slide contains a diagram of these pathways. The MAPK pathway starts with a receptor (RTK) activating Ras (GDP to GTP), which then activates Raf, MEK, and ERK. The mTOR pathway starts with PI3K activating Akt, which then activates mTOR. PTEN is shown as an inhibitor of PI3K. NF1 is shown as an inhibitor of Ras. The slide also includes a "Do Not Distribute" watermark.



Topics that will be addressed in this MTB include:

- Cancer's biology and mechanisms of action
- Frequency of alterations across tumor types
- Methodology, understanding of biomarkers, terminology (e.g. Mutant Allele Frequency, Copy Number Amplification, Purity)
- Literature review
- Associated therapies



Case selections will be based on the following criteria:

- Urgency of the treatment for the patient
- Multiple identified targets / complex genomics
- Interesting genomics in light of clinical history
- Novel alterations



# BEYOND, a randomized double-blind placebo-controlled clinical trial of the newest disease modifying drug for beta-thalassemia, Luspatercept

LANCET Haematology (impact factor 30.153), the #1 Journal in Hematology, published the results of an international clinical trial (BEYOND) led by Dr. Ali Taher as principal investigator.

BEYOND is a randomized double-blind placebo-controlled clinical trial of the newest disease modifying drug for beta-thalassemia, Luspatercept, developed by Bristol Myers Squibb (NY, USA). Luspatercept was already approved for transfusion-dependent patients [the BELIEVE trial published a year ago in NEJM with Dr. Taher as co-PI and third author. As a follow-up, the BEYOND trial came to confirm its efficacy and safety in non-transfusion-dependent patients to increase their hemoglobin levels and prevent morbidity and mortality.

One notes that over half of the cited references in the paper are actually from BHT Program previous studies, the team had been working to understand why these patients have so many clinical morbidities for over 10 years now, as summarized recently in Dr. Taher's NEJM review. So, concluding with the first treatment option for these patients is a historic milestone.

The trial is now being used to get approval of the drug in this indication in Europe, and discussions with EMA are ongoing. Accordingly, it is expected to be indicated in the Middle East sometime next year.

Articles

CrossMark

## Luspatercept for the treatment of anaemia in non-transfusion-dependent $\beta$ -thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial

Ali T Taher\*, Maria Domenica Cappellini\*, Antonis Kattamis, Ersi Voskaridou, Silverio Perrotta, Antonio G Piga, Aldo Filosa, John B Porter, Thomas D Coates, Gian Luca Forgi, Alexis A Thompson, Immacolata Tartaglione, Khaled M Musallam, Jay T Backstrom, Oriano Esposito, Ana Carolina Giuseppe, Wen-Ling Kuo, Dimana Miteva, Jennifer Lord-Bessen, Aylin Yuccel, Tatiana Zinger, Jeevan K Shetty, Vip Viprakasit, on behalf of the BEYOND Investigators†

**Summary**  
**Background** In patients with non-transfusion-dependent  $\beta$ -thalassaemia, haemoglobin concentrations lower than 10 g/dL are associated with a higher risk of morbidity, mortality, and impaired quality of life. No drugs are specifically approved for anaemia management in patients with non-transfusion-dependent  $\beta$ -thalassaemia, other than transfusion therapy administered infrequently in accordance with patients' needs. We assessed the efficacy and safety of luspatercept versus placebo in patients with non-transfusion-dependent  $\beta$ -thalassaemia.

**Methods** We did a phase 2, randomised, double-blind, multicentre, placebo-controlled trial in 12 centres in six countries (Thailand [n=1], Lebanon [n=1], Greece [n=2], Italy [n=5], the UK [n=1], and the USA [n=2]). Eligible patients were aged 18 years or older, had confirmed diagnosis of  $\beta$ -thalassaemia or haemoglobin E/ $\beta$ -thalassaemia (concomitant  $\alpha$ -globin deletion, mutation, or duplication were allowed), and a baseline haemoglobin concentration of 10.0 g/dL or lower. All patients were non-transfusion-dependent. Patients were randomly assigned (2:1) to luspatercept or placebo using an interactive response technology system and stratified by baseline haemoglobin concentration ( $\geq 8.5$  g/dL vs  $< 8.5$  g/dL) and baseline Non-Transfusion-Dependent  $\beta$ -thalassaemia-Patient-Reported Outcome Tiredness/Weakness domain score ( $\geq 3$  vs  $< 3$ ). All patients, study site staff, and sponsor representatives (who reviewed the data), except for designated individuals, were masked to drug assignment until the time the study was unblinded. Luspatercept or placebo was given once subcutaneously every 3 weeks for 48 weeks in the double-blind treatment period. Luspatercept was started at 1.0 mg/kg with titration up to 1.25 mg/kg, or reduction in the event of toxicity or excessive haemoglobin concentration increase. The primary endpoint was achievement of an increase from baseline of 1.0 g/dL or higher in mean haemoglobin concentration over a continuous 12-week interval during weeks 13–24, in the absence of transfusions. The primary efficacy and safety analyses were done in the intention-to-treat population. This trial is registered at ClinicalTrials.gov, NCT03342404, and is ongoing.

**Findings** Between Feb 5, 2018, and Oct 14, 2019, 160 patients were screened for eligibility, of whom 145 were randomly assigned to luspatercept (n=96) or placebo (n=49). 82 (57%) patients were female and 63 (43%) were male. 44 (30%) patients were Asian, 87 (60%) were White, and 14 (10%) identified as another race. The study met its primary endpoint: 74 (77%) of 96 patients in the luspatercept group and none in the placebo group had an increase of at least 1.0 g/dL in haemoglobin concentration (common risk difference 77.1 [95% CI 68.7–85.5];  $p < 0.0001$ ). The proportion of patients with serious adverse events was lower in the luspatercept group than in the placebo group (11 [12%] vs 12 [25%]). Treatment-emergent adverse events most commonly reported with luspatercept were bone pain (35 [37%]), headache (29 [30%]), and arthralgia (28 [29%]). No thromboembolic events or deaths were reported during the study.

**Interpretation** Luspatercept represents a potential treatment for adult patients with non-transfusion-dependent  $\beta$ -thalassaemia, for whom effective approved treatment options are scarce.

**Funding** Celgene and Acceleron Pharma.

**Copyright** © 2022 Published by Elsevier Ltd. All rights reserved.

**Introduction**  
 Patients with  $\beta$ -thalassaemia are commonly classified by their red blood cell transfusion requirements as having either transfusion-dependent  $\beta$ -thalassaemia or non-transfusion-dependent  $\beta$ -thalassaemia.<sup>1,2</sup> Patients with non-transfusion-dependent  $\beta$ -thalassaemia usually have less severe anaemia than do patients with transfusion-dependent  $\beta$ -thalassaemia, but most experience long-term serious health complications and impaired health-related quality of life (HRQoL).<sup>3,4</sup> Ineffective erythropoiesis and

**†A complete list of the BEYOND investigators is provided in the appendix.**

**Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon (A Taher MD); Fondazione IRCCS Ca' Granda Policlinico Hospital, University of Milan, Milan, Italy (M D Cappellini MD); First Department of Pediatrics, National and Kapodistrian University of Athens, Athens, Greece (A Kattamis MD); Thalassemia and Sickle Cell Center of Laiko General Hospital, Athens, Greece (E Voskaridou MD); Dipartimento della Donna, del Bambino e di Chirurgia Generale e Specialistica, Università della Campania, Luigi Vanvitelli, Naples, Italy (S Perrotta MD); Tarsagione MD; Department of Clinical and Biological Sciences, University of Turin, Turin, Italy (A G Piga MD); Rare Red Blood Cell Disease Unit, Cardarelli Hospital, Naples, Italy (A Filosa MD); University College London Hospitals, London, UK (J B Porter MD); Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA (T D Coates MD); University of Southern California Keck School of Medicine, Los Angeles, CA, USA**



BLADDER  
CANCER







# IN THE SPOTLIGHT

Rola Kharrouby

**Q: When did you join the Naef K. Basil Cancer Institute?**

A: July, 2015.

**Q: What is your job title?**

A: Senior Registered Nurse.

**Q: What is your main responsibilities?**

A: My responsibilities are:

Provide efficient nursing care to patients, prioritize responsibilities, anticipate needs, fulfill them.

Provide support and professional supervision to nursing staff to ensure providing optimal care.

Implement quality control measures by performing patient and environmental safety checking rounds.

**Q: Prior to joining this department, where were you working?**

A: Inpatient Pediatric Medical Surgical Department "6 \_North"

**Q: Where did you pursue your College studies?**

A: Lebanese University : Faculty of Public Health.

**Q: What do you like most about your job?**

A: Helping to make hard thing a little less difficult.

**Q: What would you like to improve in your current job?**

A: Aim to involve all the oncology patients in psychotherapy program. I believe that will ease their healing journey.

**Q: Tell us more about your ambition; in what would you like to develop your career?**

A: I would like to continue master degree in psychology.

**Q: Where is the best trip destination and why?**

A: The Maldives, it is irresistible with its emerald water, beautiful beaches, and colorful marine life.

**Q: What are your hobbies?**

A: Swimming and photography.

**Q: What would be your best food choice?**

A: Sushi.

**Q: Tell us more about your character.**

A: Honest, dedicated, assertive, team player.

**Q: What is your advice to your peers?**

A: Always take care of yourselves, eat well, have enough sleeping, and exercise. You need to be strong to take the best care of others.

**Q: What is your message to cancer patients?**

A: You are stronger than you know and Braver than you think.





# PUBLICATIONS



## Publications: July - September 2022

KIR3DL2 contributes to the typing of acute adult T-cell leukemia and is a potential therapeutic target. Cheminant M; Lhermitte L; Bruneau J; Sicard H; Bonnafous C; Touzart A; Bourbon E; Ortonne N; Genestier L; Gaulard P; Palmic P; Suarez F; Frenzel L; Naveau L; Bazarbachi A; Dussiot M; Waast L; Avettand-Fenoel V; Brouzes C; Pique C; Lepelletier Y; Asnafi V; Marçais A; Hermine O. *Blood*. 2022 Sep 29

Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP). Gavrilaki E; Labopin M; Sakellari I; Salmenniemi U; Yakoub-Agha I; Potter V; Berceanu A; Rambaldi A; Hilgendorf I; Kröger N; Mielke S; Zuckerman T; Sanz J; Busca A; Ozdogu H; Anagnostopoulos A; Savani B; Giebel S; Bazarbachi A; Spyridonidis A; Nagler A; Mohty M. *Bone Marrow Transplant*. 2022 Sep 22

Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT. Spyridonidis A; Labopin M; Brissot E; Moiseev I; Cornelissen J; Choi G; Ciceri F; Vydra J; Reményi P; Rovira M; Meijer E; Labussière-Wallet H; Blaise D; van Gorkom G; Kröger N; Koc Y; Giebel S; Bazarbachi A; Savani B; Nagler A; Mohty M. *Bone Marrow Transplant*. 2022 Sep 7

Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment. Kreidieh F; Abou Dalle I; Moukalled N; El-Cheikh J; Brissot E; Mohty M; Bazarbachi A. *Int J Hematol*. 2022 Sep

Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone in Acute Myelogenous Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Battipaglia G; Labopin M; Blaise D; Diez-Martin JL; Bazarbachi A; Vitek A; Chevallier P; Castagna L; Grillo G; Daguidau E; López-Jiménez J; Koc Y; Ruggeri A; Nagler A; Mohty M. *Transplant Cell Ther*. 2022 Sep

Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease. Mohty R; Al Hamed R; Bazarbachi A; Brissot E; Nagler A; Zeidan A; Mohty M. *J Hematol Oncol*. 2022 Aug 31

Management of Multiple Myeloma in the Middle East: Unmet Needs, Challenges and Perspective. Ibrahim A; Chamseddine N; El-Cheikh J; Hanna C; Moukadem W; Nasr F; Younis A; Bazarbachi A. *Clin Hematol Int*. 2022 Aug 30

Impact of Cytogenetic Risk on Outcomes of Non-T-Cell-Depleted Haploidentical Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Nagler A; Labopin M; Dholaria B; Ciceri F; Fraccaroli A; Blaise D; Fanin R; Bruno B; Forcade E; Vydra J; Chevallier P; Bulabois CE; Jindra P; Bornhäuser M; Canaani J; Sanz J; Savani BN; Spyridonidis A; Giebel S; Brissot E; Bazarbachi A; Esteve J; Mohty M. *Transplant Cell Ther*. 2022 Aug 27

Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia. Baron F; Labopin M; Tischer J; Ciceri F; Raiola AM; Blaise D; Sica S; Vydra J; Fanin R; Diez-Martin JL; Bulabois CE; Stölzel F; Busca A; Jindra P; Koc Y; Chevallier P; Forcade E; Rösler W; Passweg J; Kulagin A; Carella AM; Simand C; Bazarbachi A; Pioltelli P; Nagler A; Mohty M. *Bone Marrow Transplant*. 2022 Aug 17

Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia. Loke J; Labopin M; Craddock C; Cornelissen JJ; Labussière-Wallet H; Wagner-Drouet EM; Van Gorkom G; Schaap NPM; Kröger NM; Veelken JH; Rovira M; Menard AL; Bug G; Bazarbachi A; Giebel S; Brissot E; Nagler A; Esteve J; Mohty M. *Cancer*. 2022 Aug 1

Pembrolizumab for the Treatment of Relapsed and Refractory Classical Hodgkin Lymphoma After Autologous Transplant and in Transplant-Naïve Patients. Halahleh K; Al Sawajneh S; Saleh Y; Shahin O; Abufara A; Ma'koseh M; Abdel-Razeq R; Barakat F; Abdelkhaleq H; Al-Hassan N; Atiyyat R; Al-Faker N; Omari Z; Ghatasheh H; Jaradat I; Muradi I; Iyad S; Bazarbachi A. *Clin Lymphoma Myeloma Leuk*. 2022 Aug

Improved outcome in children compared to adolescents and young adults after allogeneic hematopoietic stem cell transplant for acute myeloid leukemia: a retrospective study from the Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC). Pochon C; Detrait M; Dalle JH; Michel G; Dhédin N; Chalandon Y; Brissot E; Forcade E; Sirvent A; Izzadifar-Légrand F; Michallet M; Renard C; Yakoub-Agha I; Gonzales F; Bay JO; Kanold J; Cornillon J; Bulabois CE; Angoso M; Nguyen S; Balza M; Chevallier P; Rialland F; Bazarbachi A; Beguin Y; Huynh A; Ménard AL; Schneider P; Neven B; Paillard C; Raus N; Albuissou E; Remen T; Rubio MT. *J Cancer Res Clin Oncol*. 2022 Aug

Correction: The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years. Bazarbachi A; Boumendil A; Finel H; Khvedelidze I; Romejko-Jarosinska J; Tanase A; Akhtar S; Ben Othman T; Ma'koseh M; Afanasyev B; El-Cheikh J; Briones J; Gülbas Z; Hamladji RM; Elverdi T; Blaise D; Martínez C; Alma E; Halaburda K; Sousa AB; Glass B; Robinson S; Montoto S; Sureda A. *Leukemia*. 2022 Aug

Interplay between innate immunity and the viral oncoproteins Tax and HBZ in the pathogenesis and therapeutic response of HTLV-1 associated adult T cell leukemia. El Hajj H; Bazarbachi A. *Front Immunol*. 2022

Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia. Nagler A; Peczynski C; Dholaria B; Labopin M; Valerius T; Dreger P; Kröger N; Reinhardt HC; Finke J; Franke GN; Ciceri F; Verbeek M; Blau IW; Bornhäuser M; Spyridonidis A; Bug G; Bazarbachi A; Schmid C; Yakoub-Agha I; Savani B; Mohty M. *Bone Marrow Transplant*. 2022 Jul

The efficacy and safety of BV-ICE salvage therapy for relapsed/refractory Hodgkin lymphoma. A single centre. El Cheikh J; Amhaz G; Zahreddine A; Dalle IA; Bazarbachi A. *Curr Res Transl Med*. 2022 Jul

Immunotherapy for metastatic liver disease from colorectal carcinoma: case series from the Middle East. Kakati RT; Faraj W; Qaraqe T; El Chaer F; Hussain H; Shamseddine A; Khalife MJ. *J Surg Case Rep*. 2022 Aug

The first Middle East and North Africa expert consensus recommendations for the management of advanced colorectal cancer. Kourie HR; Ibnshamsah F; Zoueini J; Naim N; Abbasi S; Allahloubi N; Al-Naqqash M; Alolayan A; Alshehri A; Bitar N; Bounedjar A; Farsi AA; Shamsi HE; Ghali R; Jaafar H; Larbaoui B; Mahrous M; Mrabti H; Nweir AR; Oukkal M; Rasul K; Razavi M; Turfa R; Khatib S;



- Shamseddine A. *Future Oncol.* 2022 Aug
- 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Farge D; Frere C; Connors JM; Khorana AA; Kakkar A; Ay C; Muñoz A; Brenner B; Prata PH; Brilhante D; Antic D; Casais P; Guillermo Esposito MC; Ikezoe T; Abutalib SA; Meillon-García LA; Bounameaux H; Pabinger I; Douketis J; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. *Lancet Oncol.* 2022 Jul
- 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Farge D; Frere C; Connors JM; Khorana AA; Kakkar A; Ay C; Muñoz A; Brenner B; Prata PH; Brilhante D; Antic D; Casais P; Guillermo Esposito MC; Ikezoe T; Abutalib SA; Meillon-García LA; Bounameaux H; Pabinger I; Douketis J; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. *Lancet Oncol.* 2022 Jul
- Crushed deferasirox film-coated tablets in pediatric patients with transfusional hemosiderosis: Results from a single-arm, interventional phase 4 study (MIMAS). Wali Y; Hassan T; Charoenkwan P; Trompeter S; Tartaglione I; Origa R; Gamberini MR; Viprakasit V; Izquierdo M; Opio S; Roy T; Taher A. *Am J Hematol.* 2022 Aug
- An open-label, multicenter, efficacy, and safety study of deferasirox in iron-overloaded patients with non-transfusion-dependent thalassemia (THETIS): 5-year results. Lai YR; Cappellini MD; Aydinok Y; Porter J; Karakas Z; Viprakasit V; Siritanaratkul N; Kattamis A; Liu R; Izquierdo M; Lasher J; Govindaraju S; Taher A. *Am J Hematol* 2022 Aug
- A pilot study on the melatonin treatment in patients with early septic shock: results of a single-center randomized controlled trial. Taher A; Shokoohmand F; Abdoli E; Mohammadi Y; Mehrpooya M. *Ir J Med Sci.* 2022 Aug
- 2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia. Farmakis D; Porter J; Taher A; Domenica Cappellini M; Angastiniotis M; Eleftheriou A. *Hemasphere.* 2022 Aug
- Challenges in implementing psycho-oncology services in Arab low- and middle-income countries: Lessons learned from Lebanon. Bizri M; Ibrahim N; El Hayek S; Saliba A; Ehlers SL; Ostroff JS; Maalouf F; Taher A. *Psychooncology.* 2022 Jul 21
- Predictors of longitudinal seizure outcomes after epilepsy surgery in childhood. Ka A; Taher A; D'Souza S; Barnes EH; Gupta S; Troedson C; Wade F; Teo O; Dale RC; Wong C; Bleasel AF; Dexter M; Kothur K; Gill D. *Epilepsy Behav Rep.* 2022
- Anhidrosis associated with long-term use of hydroxyurea in a patient with myeloproliferative neoplasm. Sabbagh S; Jarrah K; Bou-Fakhredin R; Saadeh D; Taher AT. *Ann Hematol.* 2022 Jul
- Hematological manifestations of antiphospholipid syndrome: Going beyond thrombosis. El Hasbani G; Saliba AN; Uthman I; Taher AT. *Blood Rev.* 2022 Sep 16
- Novel therapeutic diiminoquinone exhibits anticancer effects on human colorectal cancer cells in two-dimensional and three-dimensional in vitro models. Monzer A; Wakimian K; Ballout F; Al Bitar S; Yehya A; Kansa M; Saheb N; Tawil A; Doughan S; Hussein M; Mukherji D; Faraj W; Gali-Muhtasib H; Abou-Kheir W. *World J Gastroenterol.* 2022 Sep 7
- Editorial: The effects of COVID-19 on cancer research methods & strategies. Fox L; Sullivan R; Mukherji D; Van Hemelrijck M. *Front Public Health.* 2022
- Tumor profiling of KRAS, BRAF, and NRAS gene mutations in patients with colorectal cancer: A Lebanese major center cohort study. Baba O; Bidikian A; Mukherji D; Shamseddin A; Temraz S; Fakhruddin N; Khazzouh M; Ghizzawi D; Abdel Khalek R; Zaatari G; Mahfouz R. *Gene.* 2022 Aug 5
- Participation of Lower and Upper Middle-Income Countries in Clinical Trials Led by High-Income Countries. Rubagumya F; Hopman WM; Gyawali B; Mukherji D; Hammad N; Pramesh CS; Zubaryev M; Eniu A; Tsunoda AT; Kutluk T; Aggarwal A; Sullivan R; Booth CM. *JAMA Netw Open.* 2022 Aug 1
- COVID-19 and lung cancer: update on the latest screening, diagnosis, management and challenges. Moubarak S; Merheb D; Basbous L; Chamseddine N; Bou Zerdan M; Assi HI. *J Int Med Res.* 2022 Sep
- Prognostic and Predictive Biomarkers for Pancreatic Neuroendocrine Tumors. Hackeng WM; Assi HA; Westerbeke FHM; Brosens LAA; Heaphy CM. *Surg Pathol Clin.* 2022 Sep
- Treatment Strategies for Residual Disease following Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer. Abdel-Razeq H; Khalil H; Assi HI; Dargham TB. *Curr Oncol.* 2022 Aug 16
- Anouti S; Abi Jaoude J; Kayali M; Tfayli A; de Azambuja E; Poortmans P; Zeidan YH. *Int J Radiat Oncol Biol Phys.* 2022 May 1
- Talazoparib in BRCA-mutated advanced breast cancer: is earlier better? Boulos M; Moujaes E; Nsouli G; Tfayli A; Kourie HR. *Pharmacogenomics.* 2022 Jun
- A Survey on the Knowledge, Attitudes, and Practices of Lebanese Physicians Regarding Air Pollution. Assi HI; Meouchy P; El Mahmoud A; Massouh A; Bou Zerdan M; Alameh I; Chamseddine N; Kazarian H; Zeineldine S; Saliba NA; Nouredine S. *Int J Environ Res Public Health.* 2022 Jun 28
- Neurosurgical Experience of Beirut Blast in the Era of Coronavirus Disease 2019 (COVID-19) from a Tertiary Referral Center. Bsai S; Moussalem C; Kawtharani S; El Houshiemy MN; Halaoui A; Saba T; Najjar M; Assi H; Baajour J; El-Houcheimi I; Saad GA; Darwish H. *World Neurosurg.* 2022 Jun
- MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen. Kast RE; Alfieri A; Assi HI; Burns TC; Elyamany AM; Gonzalez-Cao M; Karpel-Massler G; Marosi C; Salacz ME; Sardi I; Van Vlierberghe P; Zaghloul MS; Halatsch ME. *Cancers (Basel)* . 2022 May 23
- Primary Squamous Cell Carcinoma of the Liver: Case Report and Review of Literature. Fakhreddine O; Fadlallah Y; Turfa J; Hassan MA; Chamseddine N; Assi HI. *Case Rep Oncol.* 2022 May-Aug
- Short-term outcomes following beyond total mesorectal excision and reconstruction using myocutaneous flaps: A retrospective cohort study. Assi H; Persson A; Palmquist I; Öberg M; Buchwald P; Lydrup ML. *Eur J Surg Oncol.* 2022 May
- Bilateral Pseudoarthrodesis: A Case Report of Complex Bilateral Total Knee Replacement for a Severe Hemophilia A Patient with Inhibitors. Assi H; Massé V; Saint-Yves H; Barry J; St-Louis J; Isler M. *JBJS Case Connect.* 2022 Mar 3
- Descriptive epidemiology of soft tissue and bone sarcomas in Lebanon. Bou Zerdan M; Meouchy P; Abdul Halim N; Saghie S; Sbaity E; Haidar R; Abbas J; Ibrahim A; Khalifeh M; Assi HI. *J Int Med Res.* 2022 Mar
- Pharmacologic Strategies for Post-Transplant Maintenance in Acute Myeloid Leukemia: It Is Time to Consider! Abou Dalle I; El Cheikh J; Bazarbachi A. *Cancers (Basel).* 2022 Mar 15

- 20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation. Bazarbachi A; Labopin M; Aljurf M; Niittyvuopio R; Balsat M; Blaise D; Yakoub-Agha I; Grassi A; Reinhardt HC; Lenhoff S; Jindra P; Passweg J; Abou Dalle I; Stadler M; Lioure B; Ceballos P; Brissot E; Giebel S; Nagler A; Schmid C; Mohty M. *Clin Cancer Res.* 2022 Mar 1
- Editorial: NK/T-Cell Lymphoma: Biology, Prognostics, Prediction, and Treatment. El Cheikh J; Terro K; Sharrouf L; Mishra A; De Lima M. *Front Oncol.* 2022
- Correction to: Immune checkpoint inhibitors and allogeneic transplant in lymphoid malignancies: a deceptive friend story. Farttoosi MA; El Cheikh J. *Bone Marrow Transplant.* 2022 Jun
- Systemic antifungal strategies in allogeneic hematopoietic stem cell recipients hospitalized in french hematology units: a post-hoc analysis of the cross-sectional observational AFHEM study. Michallet M; El Cheikh J; Herbrecht R; Yakoub-Agha I; Caillot D; Gangneux JP. *BMC Infect Dis.* 2022 Apr 9
- Neo-adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma. Temraz S; Nassar F; Hammoud MS; Mukherji D; O'Reilly EM; Dbouk H; Farhat F; Charafeddine M; Faraj W; Khalifeh MJ; Abou-Alfa GK; Shamseddine A. *Asia Pac J Clin Oncol.* 2022 Mar 31
- Oxaliplatin-induced thrombotic microangiopathy: a case report. Saad R; Hannun A; Temraz S; Finianos A; Zeenny RM. *J Med Case Rep.* 2022 Mar 19
18. Quality of life measures in Systemic Lupus Erythematosus: A systematic review. Radin M; El Hasbani G; Barinotti A; Roccatello D; Uthman I; Taher A; Sciascia S. *Reumatismo.* 2022 Feb 7
19. Risk of mortality from anemia and iron overload in nontransfusion-dependent  $\beta$ -thalassemia. Musallam KM; Vitrano A; Meloni A; Pollina SA; Karimi M; El-Beshlawy A; Hajipour M; Di Marco V; Ansari SH; Filosa A; Ricchi P; Ceci A; Daar S; Vlachaki E; Singer ST; Naserullah ZA; Pepe A; Scodotto S; Dardanoni G; Bonifazi F; Sankaran VG; Vichinsky E; Taher AT; Maggio A; International Working Group on Thalassemia (IWG-THAL). *Am J Hematol.* 2022 Feb 1
20. Morbidity-free survival and hemoglobin level in non-transfusion-dependent  $\beta$ -thalassemia: a 10-year cohort study. Musallam KM; Cappellini MD; Daar S; Taher AT. *Ann Hematol.* 2022 Jan
21. Primary HBB gene mutation severity and long-term outcomes in a global cohort of  $\beta$ -thalassaemia. Musallam KM; Vitrano A; Meloni A; Addario Pollina S; Di Marco V; Hussain Ansari S; Filosa A; Ricchi P; Ceci A; Daar S; Vlachaki E; Singer ST; Naserullah ZA; Pepe A; Scodotto S; Dardanoni G; Karimi M; El-Beshlawy A; Hajipour M; Bonifazi F; Vichinsky E; Taher AT; Sankaran VG; Maggio A; International Working Group on Thalassemia (IWG-THAL). *Br J Haematol.* 2022 Jan
22. Psycho-oncology in the Arab world: The time is now. El Hayek S; Dakroub A; Beaini H; Salem H; Saliba AN; Ehlers SL; Bizri M; Taher A. *Psychooncology.* 2022 Jan.
23. Post-mastectomy Radiation Therapy in Triple-Negative Breast Cancer Patients: Analysis of the BEATRICE Trial. Kayali M; Abi Jaoude J; Mohammed M; Khabba J; Tfayli A; Poortmans P; Zeidan YH. *Ann Surg Oncol.* 2022 Jan
24. Descriptive epidemiology of soft tissue and bone sarcomas in Lebanon. Bou Zerdan M; Meouchy P; Abdul Halim N; Saghie H; Sbaity E; Haidar R; Abbas J; Ibrahim A; Khalifeh M; Assi HI. *J Int Med Res.* 2022 Mar
25. Role of circulating tumor DNA and circulating tumor cells in breast cancer: History and updates. Chedid J; Allam S; Chamseddine N; Bou Zerdan M; El Nakib C; Assi HI. *SAGE Open Med.* 2022
26. Clinical Significance of Breast Cancer Molecular Subtypes and Ki67 Expression as a Predictive Value for Pathological Complete Response following Neoadjuvant Chemotherapy: Experience from a Tertiary Care Center in Lebanon. Atoui A; Bou Zerdan M; El Mahmoud A; Chamseddine N; Hamad L; Assi HI. *Int J Breast Cancer.* 2022
27. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Fahed G; Aoun L; Bou Zerdan M; Allam S; Bou Zerdan M; Bouferraa Y; Assi HI. *Int J Mol Sci.* 2022 Jan 12
28. Drug-Induced Peripheral Neuropathy: Diagnosis and Management. Merheb D; Dib G; Zerdan MB; Nakib CE; Alame S; Assi HI. *Curr Cancer Drug Targets.* 2022
29. Glioblastoma multiforme metastasizing to the skin, a case report and literature review. Nakib CE; Hajjar R; Zerdan MB; Darwish H; Zeidan Y; Alame S; Kassouf HK; Chamseddine N; Assi HI. *Radiol Case Rep.* 2022 Jan
30. The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation. Abou Dalle I; Atoui A; Bazarbachi A. *Front Oncol.* 2021
31. Progress of Hematopoietic Stem Cell Transplantation and Radiotherapy in the Treatment of Extranodal NK/T Cell Lymphoma. Terro K; Sharrouf L; El Cheikh J. *Front Oncol.* 2022
32. Hepatic granuloma mimicking recurrent lymphoma on 18F-FDG PET/CT in a patient with primary mediastinal diffuse large B-cell lymphoma. Akkawi AR; Ezzeddine L; Chahinian R; Ershaid F; Merheb D; Mzeihem M; El-Cheikh J; Haidar M. *Asia Ocean J Nucl Med Biol.* 2022 Winter
33. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Lu YS; Im SA; Colleoni M; Franke F; Bardia A; Cardoso F; Harbeck N; Hurvitz S; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; O'Regan R; Gasch C; Solovieff N; Wang C; Wang Y; Chakravarty A; Ji Y; Tripathy D. *Clin Cancer Res.* 2022 Mar 1
34. Genetic Counseling, Screening and Risk-Reducing Surgery in Patients with Primary Breast Cancer and Germline BRCA Mutations: Unmet Needs in Low- and Middle-Income Countries. Moukadem HA; Al Masry A; Atwani RW; Kreidieh F; Khalil LE; Saroufim R; Daouk S; Dalle IA; El Saghir NS. *Eur J Breast Health.* 2022 Jan
35. Inflammatory Bowel Disease: An Indication to Screen for Thrombophilia? Moukalled NM; Hashash JG; Taher AT. *Diseases.* 2022 Feb 23
36. Oxaliplatin-induced thrombotic microangiopathy: a case report. Saad R; Hannun A; Temraz S; Finianos A; Zeenny RM. *J Med Case Rep.* 2022 Mar 19
37. A Non-Interventional Multicenter Study of First-Line Bevacizumab in Combination with Chemotherapy in Patients with Metastatic Colorectal Cancer in Lebanon. Temraz S; Nasr F; Kattan J; Abigeres D; Moukadem W; Farhat F; Maatouk L; Chahine G; Shamseddine A. *Biologics.* 2022



**NAEF K. BASILE CANCER INSTITUTE**

**Telephone:** 961-1-374 374 ext. 8657/ 7903 (Administration)

**Clinic direct line:** +961-1-759618

**Email:** [nkbci@aub.edu.lb](mailto:nkbci@aub.edu.lb)

**Copyright 2022**



Our lives are dedicated to yours